Technical Data
G8950-16B
Granulocyte Colony Stimulating Factor, Recombinant, Mouse (G-CSF)
2ug
10ug
Molecular Biology Storage: -20°CShipping: RT
Granulocyte Colony Stimulating Factor (G-CSF) is a potent stimulator of bone marrow cells, especially those of neutrophil lineage. In addition, G-CSF can enhance the survival and activate the immunological functions of mature neutrophils. Murine G-CSF is a 20kD glycoprotein containing internal disulfide bonds. It induces the survival, proliferation, and differentiation of neutrophilic granulocyte precursor cells and functionally activates mature blood neutrophils. Among the family of colony-stimulating factors, G-CSF is the most potent inducer of terminal differentiation to granulocytes and macrophages of leukemic myeloid cell lines. The synthesis of G-CSF can be induced by bacterial endotoxins , TNF , Interleukin-1 and GM-CSF . Prostaglandin E2 inhibits the synthesis of G-CSF. In epithelial, endothelial, and fibroblastic cells secretion of G-CSF is induced by Interleukin-17.

Recombinant Murine G-CSF produced in E. coli is a single, non-glycosylated, polypeptide chain containing 179 amino acids and having a molecular mass of 19kD.

Protein quantitation was carried out by two independent methods:
1. UV spectroscopy at 280nm using the absorbency value of 0.51 as the extinction coefficient for a 0.1% (1mg/ml) solution. This value is calculated by the PC GENE computer analysis program of protein sequences (IntelliGenetics).
2. Analysis by RP-HPLC, using a calibrated solution of G-CSF as a Reference Standard.

Dimers and aggregates:
1% as determined by silver-stained SDS-PAGE gel.

Biological Activity:
G-CSF is fully biologically active when compared to standard. The ED50, calculated by the dose-dependent proliferation of murine NFS-60 indicator cells (measured by 3H-thymidine uptake) is 0.05ng/ml, corresponding to a Specific Activity of 2x10e7 IU/mg.

AA Sequence:
MVPLVTVSAL PPSLPLPRSF LLKSLEQVRK IQASGSVLLE QLCATYKLCH PEELVLLGHS LGIPKASLSG CSSQALQQTQ CLSQLHSGLC LYQGLLQALS GISPALAPTL DLLQLDVANF ATTIWQQMEN LGVAPTVQPT QSAMPAFTSA FQRRAGGVLA ISYLQGFLET ARLALHHLA

Storage and Stability:
Lyophilized powder may be stored at 4°C for short-term only. Reconstitute to nominal volume by adding sterile ddH2O, 0.1% HSA or BSA aliquot and store at -20°C. Reconstituted product is stable for 12 months at -20°C. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. Further dilutions can be made in assay buffer

Molecular Weight:
19.0kD
Source: Recombinant, Murine (E. coli)
Purity: 95% by RP-HPLC, Anion-exchange FPLC, reducing and non-reducing SDS-PAGE silver stained gel. Endotoxin: 0.1ng/ug (1EU/ug)
Concentration: ~1mg/ml
Form: Supplied as a lyophilized powder. No stabilizing proteins added. Reconstitute with sterile ddH2O, 0.1% HSA or BSA to a concentration of 100ug/ml, which can then be further diluted to other aqueous solutions.

Important Note: This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications without the expressed written authorization of United States Biological.
1. Subcutaneous administration of granulocyte colony stimulating factor and stem cell factor ameliorates the outcome of acute myocardial infarction. Chin Med J (Engl) 2005 Aug 5;118(15):1303-7
2. [Cyclic neutropenia with anti-NA2 antibodies and treatment with recombinant granulocyte colony-stimulating factor] An Pediatr (Barc) 2005 Aug;63(2):180-2
3. [A case of granulocyte-colony stimulating factor producing small cell carcinoma of esophagus] Nippon Shokakibyo Gakkai Zasshi 2005 Jul;102(7):888-93
4. CHOP versus CHOP plus granulocyte colony-stimulating factor in elderly patients with aggressive non-Hodgkin's lymphoma. J Clin Oncol 2005 Jul 20;23(21):4797-9; author reply 4799-800
5. Primary serous carcinoma of the peritoneum producing granulocyte colony-stimulating factor. Acta Obstet Gynecol Scand 2005 Aug;84(8):820-2
6. Granulocyte colony-stimulating factor (G-CSF) could enhance Fcgamma receptor expression in neutrophils of patients with B-cell lymphoma treated with rituximab. Leuk Lymphoma 2005 May;46(5):789-91

Intended for research use only. Not for use in human, therapeutic, or diagnostic applications.